ClinicalTrials.gg
CompletedNCT00997204EASSIUpdated Jun 11, 2021Results posted

EASSI - Evaluation of the Safety of Self-Administration With Icatibant

A Phase 3 interventional study of Icatibant in Hereditary Angioedema, sponsored by Shire. Completed at 26 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.

Enrollment
Largest of 10
151 · median 26
Started
2009
with 1 other
Phase 3
7 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
7 of 10
Shire

Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one has the largest enrollment, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 4th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About icatibant

icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing icatibant in Angioedemas, Hereditary as a file.
02

Study summary

This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.

Read the detailed description

This Phase IIIb study was multi-center and open-label with a single dose level. Subjects with a documented diagnosis of HAE Type I or II were eligible to participate in this trial. Eligible subjects included those who had received treatment for HAE with icatibant in previous clinical trials, or subjects who had been previously treated with the marketed product Firazyr® and subjects who were naïve to icatibant treatment.

All subjects were trained on the method of self-administration at their enrollment visit (Visit 1).For the training sessions, a syringe pre-filled with 3 mL placebo solution was used in place of icatibant. Comprehensive educational material and instructions including pictograms were developed for the subjects to illustrate the method of self-administration and use of the Patient Diary. The training material provided additional information on how to self-diagnose an HAE attack and how to decide on the necessity to treat.In addition, instructions were provided on what to do in case of a laryngeal attack.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • HAE
  • Type I HAE
  • Type II HAE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient must meet the following criteria to be enrolled in this study.

  1. Males and females 18 years of age at the time of
  2. Documented diagnosis of HAE Type I or II based on ALL of the following criteria:

    • Family and/or medical history
    • Characteristic attack manifestations, recurrent attacks
    • Historical functional C1-INH \<50% normal values
  3. Women of must use consistently and correctly a highly effective, adequate method of (failure rate less than 1% per year) - sexual abstinence or have a vasectomised partner during the duration of the study. Hormonal contraception can be continued if verified by a physician that it doesn't affect the course of HAE attacks.
  4. Mental and physical condition allowing patients to complete baseline assessment, to self-administer icatibant and to follow other study procedures.
  5. Ability to provide signed written informed consent after all aspects of the study have been explained and discussed with the patient.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. Participation in a clinical trial of another medicinal product within the past month (except a previous icatibant study).
  2. Diagnosis of angioedema other than Type I or Type II HAE.
  3. Evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease.
  4. Congestive heart failure ( Class 3 and 4).
  5. Stroke within the past 6 months.
  6. Treatment with angiotensin converting enzyme (ACE) inhibitor.
  7. Pregnancy and/or breast-feeding.
  8. In the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study.
  9. In the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason.
  10. In the opinion of the investigator: inability to manage study medication or self-administration of an injection.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Icatibant- Naive Treatment Phase

    Single subcutaneous injection of icatibant, 30 mg

    Drug: Icatibant

  • Experimental
    icatibant- Self administration Phase

    Single subcutaneous injection of icatibant, 30 mg

    Drug: Icatibant

Interventions

  • Single subcutaneous injection of icatibant, 30 mg

    Also known as: Brand name, Firazyr®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant

    Clinical safety of self-treatment of acute HAE attacks with s.c. injections of icatibant was assessed by calculating the number of AEs occurred during the study. Only those adverse events occurring up to the earlier of 7 days from the start of the naive phase, study discontinuation and start of the self-administration phase are assessed. The Local Tolerability Assessment tool was used. Subjects and Investigators graded erythema/reddening, swelling, burning, pruritus/itching, warm sensation, and skin pain on a 0 to 3 severity scale.

    Time frame: 7 days from the beginning of each phase

Secondary outcomes

  1. Clinical Efficacy of Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant, Time to Symptom Relief Using VAS Score for a Single Primary Symptom by Patient Cohort

    Subjects assessed angioedema attack symptoms using the visual analogue scale (VAS) for skin pain, skin swelling and abdominal pain. The VAS is a continuous scale comprised of a 100 mm in length line, anchored by 2 verbal descriptors, one for each symptom extreme 0 (no pain) and 100 (worst pain). The respondent is asked to place a mark on the VAS line (any where between 0 and 100 mm) at the point that represents their pain intensity. The score is determined by measuring the distance (mm) on the line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Score interpretation is: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). Symptom relief is defined as at least a 50% reduction in a pre-dose VAS score of 30 mm or greater. The time to onset of symptom relief is defined as the first of 3 consecutive assessments at which symptom relief was observed.

    Time frame: 48 hours post-dose

07

Results

Posted Jul 28, 2014

Participant flow

Naive Treatment Phase
Participant flow — Naive Treatment Phase
MilestoneNaive Subjects/ Naive Treatment PhaseNon-Naive Subjects/ Self-administration Phase
Started2579
Completed190
Not completed679
Self-administration Phase
Participant flow — Self-administration Phase
MilestoneNaive Subjects/ Naive Treatment PhaseNon-Naive Subjects/ Self-administration Phase
Started1978
Completed1977
Not completed01

Outcome measures

PrimaryNumber of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant

Clinical safety of self-treatment of acute HAE attacks with s.c. injections of icatibant was assessed by calculating the number of AEs occurred during the study. Only those adverse events occurring up to the earlier of 7 days from the start of the naive phase, study discontinuation and start of the self-administration phase are assessed. The Local Tolerability Assessment tool was used. Subjects and Investigators graded erythema/reddening, swelling, burning, pruritus/itching, warm sensation, and skin pain on a 0 to 3 severity scale.

Time frame:
7 days from the beginning of each phase
Reported as:
Number · participants
Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant
participantsNaive Subjects Administered Icatibant by Health Care ProviderSubjects Who Self-administered Icatibant (Naive)Subjects Who Self-administered Icatibant (Non-naive)
Number of Participants With Adverse Events in Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant11627
SecondaryClinical Efficacy of Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant, Time to Symptom Relief Using VAS Score for a Single Primary Symptom by Patient Cohort

Subjects assessed angioedema attack symptoms using the visual analogue scale (VAS) for skin pain, skin swelling and abdominal pain. The VAS is a continuous scale comprised of a 100 mm in length line, anchored by 2 verbal descriptors, one for each symptom extreme 0 (no pain) and 100 (worst pain). The respondent is asked to place a mark on the VAS line (any where between 0 and 100 mm) at the point that represents their pain intensity. The score is determined by measuring the distance (mm) on the line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. Score interpretation is: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). Symptom relief is defined as at least a 50% reduction in a pre-dose VAS score of 30 mm or greater. The time to onset of symptom relief is defined as the first of 3 consecutive assessments at which symptom relief was observed.

Time frame:
48 hours post-dose
Reported as:
Median · Hours
Clinical Efficacy of Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant, Time to Symptom Relief Using VAS Score for a Single Primary Symptom by Patient Cohort
HoursNaive Subjects Administered Icatibant by Health Care ProviderSubjects Who Self-administered Icatibant (Naive)Subjects Who Self-administered Icatibant (Non-naive)
Clinical Efficacy of Self-treatment of Acute HAE Attacks With s.c. Injections of Icatibant, Time to Symptom Relief Using VAS Score for a Single Primary Symptom by Patient Cohort2.0 (1.0 to 4.2)3.1 (2.0 to 4.0)2.0 (1.0 to 5.3)

Adverse events

Collected over 7 days from the beginning of each phase. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naive Subjects Administered Icatibant by Health Care Provider—0/22 (0%)7/22 (31.8%)
Subjects Who Self-administered Icatibant (Naive)—0/19 (0%)6/19 (31.6%)
Subjects Who Self-administered Icatibant (Non-naive)—0/78 (0%)21/78 (26.9%)
Most frequent other events
Most frequent other events
EventNaive Subjects Administered Icatibant by Health Care ProviderSubjects Who Self-administered Icatibant (Naive)Subjects Who Self-administered Icatibant (Non-naive)
Hereditary AngioedemaCongenital, familial and genetic disorders6/223/1919/78
HeadacheNervous system disorders1/221/192/78
Blood pressure increasedInvestigations0/221/190/78
Pharyngeal erythemaRespiratory, thoracic and mediastinal disorders0/221/190/78
Feeling HotGeneral disorders0/221/190/78
Local SwellingGeneral disorders0/221/190/78
Edema PeripheralGeneral disorders0/221/190/78
Localized edemaGeneral disorders0/221/190/78
Skin LesionSkin and subcutaneous tissue disorders0/221/190/78
Laryngeal edemaRespiratory, thoracic and mediastinal disorders0/221/190/78

Baseline characteristics

Age, Continuous
Age, Continuous(years)Non-Naive PatientsNaive PatientsTotal
Mean40.607 ± 13.04444.68 ± 16.5341.58 ± 13.98
Sex: Female, Male
Sex: Female, Male(Participants)Non-Naive PatientsNaive PatientsTotal
Female521668
Male27936
Region of Enrollment
Region of Enrollment(Participants)Non-Naive PatientsNaive PatientsTotal
France606
Argentina18523
Spain9211
Denmark505
Austria9514
Israel15015
Germany9514
Italy112
Switzerland112
United Kingdom6612
08

Study locations

26 sites
  • Hospital Britanico Unidad de Alergia
    Buenos Aires, C1035AAT, Argentina
  • Universitätsklinik für Dermatologie und Venerologie
    Graz, 8036, Austria
  • Odense Universitetshospital-OUH
    Odense, I Og Alergicentret, Denmark
  • Centre Hospitalier Universitaire/ Service de Dermatologie
    Angers, Angers Cedex 09 49933, France
  • Hospital Edouaed Herriot
    Lyon, Cedex 03 69437, France
  • Clinique Universitaire de Medicine/ Centre National de reference
    Grenoble, Grenoble Cedex 09 38043, France
  • Hopital Claude Huriex/ Service de medicine interne
    Lille, Lille Cedex 59037, France
  • Hopital Europeen Georges Pompidou Immunologie Clinique
    Paris, Paris Cedex 15 75015, France
  • Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, Charité
    Berlin, 10117, Germany
  • Universitäts-Hals-Nasen-Ohren-Klinik Essen, Universität Duisburg-Essen
    Essen, 45127, Germany
  • Klinkum der Johann Wolfgang Goethe-Universitat
    Frankfurt am Main, 60590, Germany
  • Hautklinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität
    Mainz, 55101, Germany
  • Bnai-Zion M.C. Clinical Immunology and Allergy Division
    Haifa, 31048, Israel
  • Tel Aviv Sourasky Medical Center - Allergy Unit
    Tel Aviv, 64239, Israel
  • The Chaim Sheba Medical Center, The Allergy and Clinical Immunology Unit
    Tel Hashomer, 52621, Israel
  • Ospedale Luigi Sacco
    Milano, 20157, Italy
  • Universita degli Studi di Napoli 'Federico II'
    Napoli,, 80131, Italy
  • Hospital Universitario Vall de Hebrón / Sección de Alergia, Escola Infermeria
    Barcelona, 08035, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario La Paz, Servicio de Alergia
    Madrid, 28046, Spain
  • Hospital Universitario La Fe, Servicio de Alergia
    Valencia, 46009, Spain
  • Luzerner Kantonsspital
    Luzern, Switzerland
  • Universitätsspital Zürich / Dermatologische Klinik
    Zurich, 8091, Switzerland
  • Southmead Hospital, Department of Immunology
    Bristol, BS10 5NB, United Kingdom
  • Barts & The London NHS Trust, Pathology and Pharmacy Building
    London, E1 2ES, United Kingdom
  • Derriford Combined Laboratory, Department of Clinical Immunology & Allergy
    Plymouth, PL6 8DH, United Kingdom
09

References and documents

Publications

  • Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbran A. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy. 2014 Mar;69(3):305-14. doi: 10.1111/all.12303. PubMed 24438203 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2009 to primary completion in Jun 2011, 20 months.

Results were first posted in Jul 2014, 3 years 1 month after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 20 months is close to that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2009
First posted
Oct 19, 2009
StartActual
Sep 25, 2009
Primary completionActual
Jun 22, 2011
CompletionActual
Jun 22, 2011
Results first posted
Jul 28, 2014
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00997204
Lead sponsor
Shire
Collaborators
Jerini AG
Responsible party
Sponsor
First posted
Oct 19, 2009
Start date
Sep 25, 2009
Primary completion
Jun 22, 2011
Completion
Jun 22, 2011
Results posted
Jul 28, 2014
Last update
Jun 11, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion